112885-42-4 Usage
Description
Mosapride citrate is a gastroprokinetic agent that functions as a selective serotonin (5-HT) receptor subtype 5-HT4 agonist. It is characterized by its high selectivity for the 5-HT4 receptor over other receptors such as 5-HT1, 5-HT2, dopamine D2, and α1and α2-adrenergic receptors. Mosapride citrate also exhibits partial antagonist activity at the 5-HT3 receptor. Mosapride citrate is known to induce relaxation in precontracted rat esophageal thoracic muscularis mucosa preparations and enhance electrically evoked contractions in isolated guinea pig ileum. In addition, it has been shown to increase antral and duodenal motility in conscious dogs and accelerate gastric emptying in rats.
Uses
Used in Pharmaceutical Industry:
Mosapride citrate is used as a gastroprokinetic agent for the treatment of various gastrointestinal disorders. Its primary applications include the treatment of acid reflux, irritable bowel syndrome, and functional dyspepsia. As a selective 5HT4 agonist, it accelerates gastric emptying, which aids in alleviating the symptoms associated with these conditions.
Used in Gastrointestinal Motility Enhancement:
Mosapride citrate is used as a motility enhancer to improve the movement of food through the gastrointestinal tract. Its ability to increase antral and duodenal motility in conscious dogs and accelerate gastric emptying in rats makes it a valuable compound for treating conditions characterized by impaired gastrointestinal motility.
Used in Acid Reflux Treatment:
Mosapride citrate is used as a therapeutic agent for the treatment of acid reflux. By accelerating gastric emptying and improving gastrointestinal motility, it helps to reduce the frequency and severity of acid reflux symptoms.
Used in Irritable Bowel Syndrome Management:
Mosapride citrate is used as a management agent for irritable bowel syndrome (IBS). Its role as a selective 5HT4 agonist helps to regulate the movement of the gut, which can provide relief from the symptoms of IBS, such as abdominal pain, bloating, and altered bowel habits.
Used in Functional Dyspepsia Treatment:
Mosapride citrate is used as a treatment option for functional dyspepsia, a condition characterized by chronic indigestion and discomfort in the upper abdomen. Its ability to enhance gastrointestinal motility and accelerate gastric emptying can help alleviate the symptoms of functional dyspepsia.
Biological Activity
5-HT 4 receptor agonist and 5-HT 3 receptor antagonist. Displays no activity at D 2 , α 1 , α 2 , 5-HT 1 and 5-HT 2 receptors. Gastroprokinetic agent; increases gastric emptying in rats and stimulates gastric motor actvity in conscious dogs.
Check Digit Verification of cas no
The CAS Registry Mumber 112885-42-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,2,8,8 and 5 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 112885-42:
(8*1)+(7*1)+(6*2)+(5*8)+(4*8)+(3*5)+(2*4)+(1*2)=124
124 % 10 = 4
So 112885-42-4 is a valid CAS Registry Number.
InChI:InChI=1/C21H25ClFN3O3.C6H8O7.2H2O/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14;7-3(8)1-6(13,5(11)12)2-4(9)10;;/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);2*1H2
112885-42-4Relevant articles and documents
Synthesis method of mosapride citrate
-
, (2020/07/15)
The invention provides a preparation method of mosapride citrate, namely 4-amino-5-chloro-2-ethoxy-N-((4-(4-fluorophenyl)morpholin-2-yl)methyl)benzamide citrate. The method provided by the invention has the advantages of cheap and easily available raw materials, short reaction steps, high yield, simple post-treatment and the like, reduces the cost, has certain technical advantages, and is suitablefor large-scale industrial production.
Citric acid mosapride intermediate product and application
-
, (2018/09/08)
The invention belongs to the field of medical chemistry synthesis, and provides a preparation method of citric acid mosapride intermediate product IV 4-[(4-fluorophenyl)methyl]-2-morpholinemethanaminesalt and citric acid mosapride. The 2-(4-fluorobenzoamido)ethanol and 1H-Isoindole-1,3(2H)-dione,2-(2-oxiranylmethyl) are taken as raw materials, and the intermediate product IV 4-[(4-fluorophenyl)methyl]-2-morpholinemethanamine salt is obtained after acid treating is conducted; the intermediate product IV and an intermediate V 2-oxethyl-4-acetamido-5-Chlorobenzoic acid ethyl ester compounds aretaken as raw materials, dichloromethane is taken as a solvent, and EDCI and DMAP are taken as catalysts to prepare mosapride salt; the mosapride salt is reacted with citric acid aqueous solution to prepare citric acid mosapride. The intermediate product has the advantages that products are high in yield, raw materials are easy to obtain, the production cost is low, and the intermediate product issuitable for industrialized production.
HIGHLY PURE MOSAPRIDE CITRATE DIHYDRATE AND PROCESSES FOR ITS PREPARATION
-
Page/Page column 11, (2011/10/03)
The present invention provides for highly pure mosapride citrate dihydrate and processes for its preparation. The present invention further provides a process for the preparation of mosapride citrate dihydrate substantially free of impurity D-II.